ALS patients losing time and hope as they wait for insurers to cover a pricey new drug image

STAT, May 21, 2018
Ed Silverman, quoting I. Glenn Cohen (Faculty Director)


Read the Full Article

From the article:

For the past two years, Sarah Benoit has been getting around with the help of a walker, waiting for a medicine that’s out of reach.

Benoit, a former congressional aide, has ALS, a fatal neurological disease that gradually causes muscle weakness and paralysis. As it progresses, she struggles to maintain a normal life, but holds out hope that a drug called Radicava — the first new treatment in 22 years — will slow her deterioration.

“The problem is the way the system creates incentives for both drug makers and insurers to act as they do,” said I. Glenn Cohen, a Harvard Law School professor who is an expert in bioethics and health law policy. “When you allow private insurers to make decisions with only a patchwork of state regulations, they will choose not to cover every drug approved by the FDA. And drug companies are for-profit entities that set prices based on market conditions. This is why you have debates over coverage.”

Read the full article here!


health care finance i. glenn cohen pharmaceuticals public health